TriSalus Life Sciences (TLSI) Revenue (2022 - 2026)

TriSalus Life Sciences has reported Revenue for 5 years, with the latest figure at $8.9 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 2.92% year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2026 stood at $44.9 million (up 39.64% YoY), and the FY2025 full-year result was $45.2 million, up 53.41% from the prior year.
• Revenue for Q1 2026 stood at $8.9 million, down from $13.2 million in the prior quarter.
• The five-year high for Revenue was $13.2 million in Q4 2025, with the low at $3.0 million in Q1 2023.
• Historically, Revenue has averaged $7.3 million across 5 years, with a median of $7.3 million in 2024.
• Annual changes were most pronounced in 2024 — Revenue surged 116.39% — and 2026, when it fell 2.92%.
• TriSalus Life Sciences' Revenue stood at $3.2 million in 2022, then jumped by 77.34% to $5.7 million in 2023, then surged by 44.4% to $8.3 million in 2024, then jumped by 59.85% to $13.2 million in 2025, then tumbled by 32.61% to $8.9 million in 2026.
• The last three Revenue figures came in at $8.9 million (Q1 2026), $13.2 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.